- Home
- HTGC vs MIRM Comparison
HTGC vs MIRM Comparison
Compare HTGC & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTGC
- MIRM
- Stock Information
- Founded
- HTGC 2003
- MIRM 2018
- Country
- HTGC United States
- MIRM United States
- Employees
- HTGC N/A
- MIRM N/A
- Industry
- HTGC Investment Managers
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- HTGC Finance
- MIRM Health Care
- Exchange
- HTGC Nasdaq
- MIRM Nasdaq
- Market Cap
- HTGC 3.5B
- MIRM 3.8B
- IPO Year
- HTGC 2005
- MIRM 2019
- Fundamental
- Price
- HTGC $17.59
- MIRM $72.20
- Analyst Decision
- HTGC Buy
- MIRM Strong Buy
- Analyst Count
- HTGC 8
- MIRM 11
- Target Price
- HTGC $21.19
- MIRM $79.00
- AVG Volume (30 Days)
- HTGC 1.4M
- MIRM 580.7K
- Earning Date
- HTGC 10-30-2025
- MIRM 11-04-2025
- Dividend Yield
- HTGC 10.59%
- MIRM N/A
- EPS Growth
- HTGC N/A
- MIRM N/A
- EPS
- HTGC 1.52
- MIRM N/A
- Revenue
- HTGC $504,002,000.00
- MIRM $429,161,000.00
- Revenue This Year
- HTGC $9.13
- MIRM $53.14
- Revenue Next Year
- HTGC $6.61
- MIRM $19.83
- P/E Ratio
- HTGC $11.71
- MIRM N/A
- Revenue Growth
- HTGC 3.72
- MIRM 62.33
- 52 Week Low
- HTGC $15.65
- MIRM $36.88
- 52 Week High
- HTGC $22.04
- MIRM $78.55
- Technical
- Relative Strength Index (RSI)
- HTGC 42.82
- MIRM 43.37
- Support Level
- HTGC $17.59
- MIRM $68.34
- Resistance Level
- HTGC $18.12
- MIRM $71.86
- Average True Range (ATR)
- HTGC 0.27
- MIRM 2.36
- MACD
- HTGC 0.09
- MIRM -0.43
- Stochastic Oscillator
- HTGC 59.85
- MIRM 28.92
About HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.